9th Annual BMRP Investigator Meeting - Abstract
Vitamin D Supplementation as Non-Toxic Immunomodulation in Children with Crohn’s Disease
David Ziring1,a, Emily Levy1, Venu Lagishetty2, John S Adams2 and Martin Hewison2
Departments of 1Pediatrics and 2Orthopedic Surgery, David Geffen School of Medicine, University of California, Los Angeles (Los Angeles, California, U.S.A)
While vitamin D is important for skeletal health in patients with Crohn’s disease, its role in immune homeostasis in these patients has been underappreciated. Both Crohn’s disease and vitamin D deficiency share similar perturbations in both the innate and acquired immune systems. Direct effects of vitamin D, mediated via the intracellular vitamin D receptor, include induction of the anti-microbial peptide cathelicidin in monocytes. Our aims for this pilot study are to enroll 20 children ages 8 to 18 years with mild to moderate Crohn’s disease in a study of vitamin D supplementation as non-toxic immunomodulation. Primary endpoints will be analysis of serum levels of the main circulating form of vitamin D, 25-OH vitamin D, as well as changes in patient monocyte cathelicidin mRNA expression and serum cathelicidin protein levels. Secondary endpoints will include changes in disease activity scores, inflammatory markers, and serum cytokine concentration. To date, we have screened and enrolled several patients and have collected clinical data and batched biologic specimens for future analysis. Barriers to enrollment include strict inclusion criteria of children with mild to moderate disease activity on stable medication regimens, and patient and parent acceptance. Final results are pending at this time.
a Principal Investigator